What is the current valuation of the US seropositive rheumatoid-arthritis-drug market?

The market valuation was $4500.0 Million in 2024. Read More

What is the projected market size for the US seropositive rheumatoid-arthritis-drug market by 2035?

The market is projected to reach $8000.0 Million by 2035. Read More

Which drug class had the highest valuation in the US seropositive rheumatoid-arthritis-drug market in 2024?

Biologics had the highest valuation, ranging from $2700.0 Million to $4200.0 Million. Read More

What are the two main treatment types in the US seropositive rheumatoid-arthritis-drug market?

The two main treatment types are Monotherapy and Combination Therapy. Read More

What was the valuation range for Combination Therapy in the US seropositive rheumatoid-arthritis-drug market in 2024?

Combination Therapy had a valuation range of $2700.0 Million to $4800.0 Million. Read More

Which administration route generated the highest revenue in the US seropositive rheumatoid-arthritis-drug market in 2024?

The Injectable route generated the highest revenue, with a range of $2250.0 Million to $4000.0 Million. Read More

What is the valuation range for the Adult patient age group in the US seropositive rheumatoid-arthritis-drug market?

The valuation range for the Adult patient age group was $2700.0 Million to $4800.0 Million. Read More

Who are the key players in the US seropositive rheumatoid-arthritis-drug market?

Key players include AbbVie, Roche, Pfizer, Bristol-Myers Squibb, Sanofi, Novartis, Johnson & Johnson, and Amgen. Read More

What is the valuation range for Non-Steroidal Anti-Inflammatory Drugs in the US seropositive rheumatoid-arthritis-drug market?

The valuation range for Non-Steroidal Anti-Inflammatory Drugs was $900.0 Million to $1600.0 Million. Read More

US Seropositive Rheumatoid Arthritis Drug Market

Q: What is the expected CAGR for the US seropositive rheumatoid-arthritis-drug market during the forecast period 2025 - 2035?

The expected CAGR is 5.37% during the forecast period. Read More

ID: MRFR/Pharma/16786-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Seropositive Rheumatoid Arthritis Drug Market Research Report: By Drug Class (Nsaid, Dmards, Biologics) - Growth & Industry Forecast 2025 To 2035

US Seropositive Rheumatoid Arthritis Drug Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Drug Class (USD Million)
  1. 4.1.1 Non-Steroidal Anti-Inflammatory Drugs
  2. 4.1.2 Disease-Modifying Anti-Rheumatic Drugs
  3. 4.1.3 Biologics
2. 4.2 Chemicals and Materials, BY Treatment Type (USD Million)
  1. 4.2.1 Monotherapy
  2. 4.2.2 Combination Therapy
3. 4.3 Chemicals and Materials, BY Administration Route (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Injectable
  3. 4.3.3 Topical
4. 4.4 Chemicals and Materials, BY Patient Age Group (USD Million)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
  3. 4.4.3 Geriatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Johnson & Johnson (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
5. 6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY PATIENT AGE GROUP, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Drug Class (USD Million, 2025-2035)

Non-Steroidal Anti-Inflammatory Drugs
Disease-Modifying Anti-Rheumatic Drugs
Biologics

Chemicals and Materials By Treatment Type (USD Million, 2025-2035)

Monotherapy
Combination Therapy

Chemicals and Materials By Administration Route (USD Million, 2025-2035)

Oral
Injectable
Topical

Chemicals and Materials By Patient Age Group (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”